Teva Pharmaceutical Industries Limited (TEVA) has disclosed a new risk, in the Litigation & Legal Liabilities category.
Teva Pharmaceutical Industries Limited faces significant business risk due to ongoing governmental and civil proceedings and litigations. These legal challenges, stemming from various aspects of their operations such as marketing practices and product liability, not only drain financial resources but also distract management and can lead to substantial fines and operational disruptions. The growing trend in securities claims and event-driven litigation has resulted in higher insurance premiums and deductibles, potentially affecting Teva’s ability to secure favorable insurance terms. The uncertainty and potential insufficiency of insurance coverage to fully address claims exacerbate the financial and operational risks for the company.
Overall, Wall Street has a Moderate Buy consensus rating on TEVA stock based on 6 Buys, 1 Sell and 2 Holds.
To learn more about Teva Pharmaceutical Industries Limited’s risk factors, click here.
